Soleno shares jump 33% as Neurocrine expands into metabolic diseases with $2.9 billion buyout

Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 ​billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker’s expansion into metabolic disorders.